RBC Capital Initiates Coverage On Corbus Pharmaceuticals With Outperform Rating, Announces Price Target of $77
RBC Capital Initiates Coverage On Corbus Pharmaceuticals With Outperform Rating, Announces Price Target of $77
加拿大皇家銀行資本以跑贏大盤的評級啓動對Corbus製藥的報道,宣佈目標股價爲77美元
RBC Capital analyst Brian Abrahams initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform rating and announces Price Target of $77.
加拿大皇家銀行資本分析師布萊恩·亞伯拉罕斯以跑贏大盤的評級啓動了對Corbus Pharmicals(納斯達克股票代碼:CRBP)的報道,並宣佈目標股價爲77美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。